Header Logo

Parameswaran Venugopal

Concepts (236)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Combined Chemotherapy Protocols
19
2023
244
1.850
Why?
Lymphoma, Non-Hodgkin
8
2019
37
1.200
Why?
Leukemia, Myeloid, Acute
5
2021
50
1.190
Why?
Arabinonucleosides
4
2021
6
0.980
Why?
Lymphoma
3
2023
38
0.960
Why?
Antibodies, Monoclonal
8
2011
199
0.960
Why?
Lymphoma, Large B-Cell, Diffuse
6
2019
35
0.950
Why?
Central Nervous System Neoplasms
3
2023
10
0.950
Why?
Rituximab
16
2023
50
0.930
Why?
Antineoplastic Agents
5
2022
190
0.790
Why?
Antibodies, Monoclonal, Murine-Derived
11
2017
29
0.760
Why?
Adenine Nucleotides
2
2010
2
0.690
Why?
Burkitt Lymphoma
3
2021
7
0.560
Why?
Paraproteinemias
2
2019
6
0.540
Why?
Insulin-Like Growth Factor Binding Proteins
1
2015
10
0.490
Why?
Insulin-Like Growth Factor I
1
2015
59
0.470
Why?
Middle Aged
25
2023
9322
0.460
Why?
Adult
21
2021
8173
0.440
Why?
Treatment Outcome
18
2021
3622
0.440
Why?
Humans
43
2023
28554
0.430
Why?
Aged
22
2023
9344
0.420
Why?
Male
25
2022
15401
0.390
Why?
Cyclophosphamide
9
2021
51
0.380
Why?
Necrobiotic Xanthogranuloma
1
2011
2
0.380
Why?
Plasma Cells
1
2011
6
0.380
Why?
Mediastinum
1
2011
7
0.380
Why?
Lymphoma, Mantle-Cell
1
2011
2
0.380
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
3
2022
15
0.360
Why?
Doxorubicin
7
2021
55
0.350
Why?
Female
26
2021
15821
0.340
Why?
Arsenicals
2
2007
12
0.340
Why?
Oxides
2
2007
18
0.340
Why?
Cranial Irradiation
2
2007
13
0.330
Why?
Aged, 80 and over
11
2023
4901
0.330
Why?
Vincristine
7
2019
21
0.330
Why?
Prednisone
7
2019
65
0.320
Why?
Lymphohistiocytosis, Hemophagocytic
1
2008
9
0.310
Why?
Cachexia
2
2019
13
0.300
Why?
Disease-Free Survival
7
2021
177
0.290
Why?
Kaplan-Meier Estimate
5
2021
180
0.290
Why?
Leukemia, Myelomonocytic, Acute
1
2007
1
0.280
Why?
Sarcoma, Myeloid
1
2007
4
0.280
Why?
Ear Neoplasms
1
2007
7
0.280
Why?
Lymphoproliferative Disorders
2
2023
13
0.280
Why?
Brain Neoplasms
2
2006
88
0.270
Why?
Epstein-Barr Virus Infections
2
2023
10
0.270
Why?
Recurrence
6
2020
322
0.270
Why?
Purpura, Thrombotic Thrombocytopenic
1
2006
10
0.260
Why?
HIV Infections
2
2021
490
0.260
Why?
Drug Administration Schedule
6
2019
166
0.260
Why?
Biomarkers
3
2019
601
0.240
Why?
Combined Modality Therapy
4
2019
308
0.240
Why?
Immunotherapy
2
2008
56
0.230
Why?
Prognosis
6
2021
827
0.230
Why?
Lymphomatoid Granulomatosis
1
2003
2
0.220
Why?
Lymphoma, B-Cell
3
2008
9
0.220
Why?
Proto-Oncogene Proteins c-myc
2
2021
16
0.210
Why?
Remission Induction
6
2015
90
0.200
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
3
2011
17
0.190
Why?
Drug Resistance, Neoplasm
3
2020
63
0.180
Why?
Thrombosis
1
2021
58
0.180
Why?
Deubiquitinating Enzymes
1
2020
1
0.170
Why?
Benzylidene Compounds
1
2020
1
0.170
Why?
Azepines
1
2020
3
0.170
Why?
Multiple Myeloma
1
2020
21
0.170
Why?
Retrospective Studies
5
2023
3615
0.160
Why?
Folic Acid Deficiency
1
2019
7
0.160
Why?
Phthalazines
1
2019
6
0.160
Why?
Graft vs Host Disease
1
2020
55
0.160
Why?
Central Nervous System
3
2023
59
0.160
Why?
Respiratory Insufficiency
1
2020
52
0.160
Why?
Proportional Hazards Models
2
2017
352
0.160
Why?
Proto-Oncogene Proteins c-bcl-2
1
2019
20
0.160
Why?
Young Adult
4
2021
2104
0.160
Why?
Piperazines
1
2019
80
0.150
Why?
Hematopoietic Stem Cell Transplantation
1
2020
117
0.150
Why?
Neutropenia
4
2012
19
0.150
Why?
Cytosine
2
2021
5
0.150
Why?
Neoplasm Recurrence, Local
3
2021
206
0.150
Why?
Medical Oncology
1
2018
43
0.150
Why?
Kidney Diseases
1
2019
109
0.150
Why?
Cardiology
1
2018
57
0.140
Why?
Immunity
1
2017
15
0.140
Why?
Bendamustine Hydrochloride
1
2016
8
0.140
Why?
Immunocompromised Host
1
2017
45
0.140
Why?
Stroke Volume
1
2016
58
0.130
Why?
Biopsy
2
2019
220
0.130
Why?
Registries
1
2017
188
0.130
Why?
Feasibility Studies
2
2019
233
0.130
Why?
Induction Chemotherapy
1
2015
13
0.120
Why?
Hematologic Neoplasms
1
2014
19
0.120
Why?
Myelodysplastic Syndromes
2
2004
33
0.110
Why?
Metabolic Syndrome
1
2014
62
0.110
Why?
Herpesvirus 4, Human
2
2023
8
0.110
Why?
Leukopenia
2
2011
6
0.110
Why?
Lymphoma, Follicular
2
2011
4
0.110
Why?
Methotrexate
2
2023
36
0.110
Why?
Transcription Factors
2
2004
172
0.100
Why?
Cytarabine
3
2023
11
0.100
Why?
Daunorubicin
2
2015
5
0.100
Why?
Hemoglobinuria, Paroxysmal
1
2012
2
0.100
Why?
Transcriptome
1
2012
87
0.100
Why?
DNA-Binding Proteins
2
2004
274
0.100
Why?
Diabetes Mellitus, Type 2
1
2014
191
0.100
Why?
Agranulocytosis
1
2011
3
0.090
Why?
Lymphoma, B-Cell, Marginal Zone
1
2011
6
0.090
Why?
Yttrium Radioisotopes
1
2011
10
0.090
Why?
Obesity
1
2014
322
0.090
Why?
Fatal Outcome
2
2008
57
0.090
Why?
Cytokines
1
2012
232
0.090
Why?
Retreatment
1
2010
8
0.090
Why?
Salvage Therapy
1
2010
36
0.090
Why?
Pilot Projects
1
2011
438
0.080
Why?
Platelet Count
2
2007
16
0.080
Why?
Infusions, Intravenous
2
2020
53
0.070
Why?
Tretinoin
1
2007
15
0.070
Why?
Injections, Spinal
1
2007
32
0.070
Why?
Weight Loss
2
2019
130
0.070
Why?
Tomography, X-Ray Computed
1
2011
772
0.070
Why?
Vascular Neoplasms
1
2006
4
0.070
Why?
Severity of Illness Index
2
2021
990
0.070
Why?
ADAMTS13 Protein
1
2006
5
0.070
Why?
Plasma Exchange
1
2006
12
0.060
Why?
Follow-Up Studies
1
2011
1863
0.060
Why?
ADAM Proteins
1
2006
41
0.060
Why?
Hemoglobins
1
2006
78
0.060
Why?
Immunosuppressive Agents
2
2023
140
0.060
Why?
Autoantibodies
1
2006
80
0.060
Why?
Survival Analysis
2
2019
267
0.060
Why?
Twins, Dizygotic
1
2005
3
0.060
Why?
Radiography
1
2007
651
0.060
Why?
Proto-Oncogenes
1
2004
4
0.060
Why?
Kidney Transplantation
1
2006
132
0.060
Why?
Thalidomide
1
2004
6
0.060
Why?
United States
2
2021
2191
0.060
Why?
Cohort Studies
2
2021
1942
0.060
Why?
Etoposide
2
2019
26
0.060
Why?
Peripheral Blood Stem Cell Transplantation
1
2004
1
0.060
Why?
Antigens, CD20
1
2003
4
0.060
Why?
Epilepsy, Tonic-Clonic
1
2003
5
0.060
Why?
Vision Disorders
1
2003
22
0.060
Why?
Antigens, Neoplasm
1
2003
39
0.050
Why?
Cyclin D1
1
2003
5
0.050
Why?
Cell Cycle Proteins
1
2003
16
0.050
Why?
K562 Cells
1
2003
3
0.050
Why?
Telomerase
1
2003
9
0.050
Why?
Histones
1
2003
28
0.050
Why?
Apoptosis
1
2003
205
0.050
Why?
Bridged Bicyclo Compounds, Heterocyclic
1
2022
1
0.050
Why?
Cerebral Cortex
1
2003
165
0.050
Why?
Voriconazole
1
2022
12
0.050
Why?
Sulfonamides
1
2022
41
0.050
Why?
Azacitidine
1
2021
10
0.050
Why?
United Kingdom
1
2021
52
0.050
Why?
Risk Factors
2
2005
2414
0.050
Why?
L-Lactate Dehydrogenase
1
2021
6
0.050
Why?
Gene Rearrangement
1
2021
10
0.050
Why?
Incidence
1
2023
774
0.040
Why?
Thrombocytopenia
2
2012
22
0.040
Why?
Postoperative Complications
1
2006
934
0.040
Why?
Folic Acid
1
2019
21
0.040
Why?
Monoclonal Gammopathy of Undetermined Significance
1
2019
2
0.040
Why?
Kidney Function Tests
1
2019
22
0.040
Why?
Maintenance Chemotherapy
1
2019
1
0.040
Why?
Translocation, Genetic
1
2019
5
0.040
Why?
Immunoglobulin A
1
2019
13
0.040
Why?
Maximum Tolerated Dose
1
2019
13
0.040
Why?
Symptom Assessment
1
2019
20
0.040
Why?
Anemia
2
2012
94
0.040
Why?
Activities of Daily Living
1
2023
612
0.040
Why?
Transplantation, Homologous
1
2020
286
0.040
Why?
Vidarabine
2
2011
9
0.040
Why?
Body Composition
1
2019
69
0.040
Why?
Sarcopenia
1
2019
31
0.040
Why?
Interdisciplinary Communication
1
2018
23
0.040
Why?
Cardiologists
1
2018
8
0.040
Why?
Mitoxantrone
2
2011
4
0.040
Why?
Ovarian Neoplasms
1
2019
70
0.040
Why?
Lung Neoplasms
1
2003
552
0.040
Why?
Magnetic Resonance Imaging
1
2003
1197
0.040
Why?
Disease Management
1
2019
115
0.040
Why?
Bortezomib
1
2017
3
0.040
Why?
Sex Factors
1
2019
477
0.040
Why?
Tomography, Emission-Computed
2
2006
9
0.030
Why?
Disease Progression
2
2012
722
0.030
Why?
Prospective Studies
2
2015
1811
0.030
Why?
Neoplasms
1
2019
241
0.030
Why?
Recombinant Proteins
2
2008
215
0.030
Why?
Naphthalimides
1
2015
1
0.030
Why?
Organophosphonates
1
2015
1
0.030
Why?
Adenine
1
2015
2
0.030
Why?
Adolescent
1
2021
2323
0.030
Why?
Sensitivity and Specificity
2
2006
520
0.030
Why?
Lipid Metabolism
1
2014
38
0.030
Why?
Insulin Resistance
1
2014
52
0.030
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2004
140
0.030
Why?
Cytogenetic Analysis
1
2012
5
0.030
Why?
Administration, Oral
1
2012
111
0.020
Why?
RNA, Messenger
2
2003
310
0.020
Why?
Signal Transduction
1
2014
447
0.020
Why?
Pneumonia
1
2012
77
0.020
Why?
Radiopharmaceuticals
1
2011
54
0.020
Why?
Time Factors
1
2015
1498
0.020
Why?
Nausea
1
2007
24
0.020
Why?
Methylprednisolone
1
2007
22
0.020
Why?
Creatinine
1
2007
53
0.020
Why?
Cisplatin
1
2007
53
0.020
Why?
Animals
1
2014
3814
0.020
Why?
Dose-Response Relationship, Drug
1
2006
352
0.020
Why?
MDS1 and EVI1 Complex Locus Protein
1
2004
3
0.010
Why?
Zinc Fingers
1
2004
12
0.010
Why?
Cell Lineage
1
2004
24
0.010
Why?
Spleen
1
2004
34
0.010
Why?
Teniposide
1
2004
1
0.010
Why?
Bleomycin
1
2004
2
0.010
Why?
Interferon-alpha
1
2004
32
0.010
Why?
Drug Therapy, Combination
1
2004
184
0.010
Why?
Neoplasm Staging
1
2005
372
0.010
Why?
Patient Selection
1
2005
207
0.010
Why?
S Phase
1
2003
10
0.010
Why?
E2F Transcription Factors
1
2003
5
0.010
Why?
Transplantation, Autologous
1
2004
170
0.010
Why?
E2F1 Transcription Factor
1
2003
5
0.010
Why?
Retinoblastoma Protein
1
2003
11
0.010
Why?
Karyotyping
1
2003
9
0.010
Why?
Granulocytes
1
2003
16
0.010
Why?
DNA Primers
1
2003
50
0.010
Why?
In Situ Hybridization, Fluorescence
1
2003
34
0.010
Why?
Bone Marrow Cells
1
2003
51
0.010
Why?
Cell Nucleus
1
2003
79
0.010
Why?
Blotting, Western
1
2003
148
0.010
Why?
Transcription, Genetic
1
2003
107
0.010
Why?
Polymerase Chain Reaction
1
2003
119
0.010
Why?
Bone Marrow
1
2003
81
0.010
Why?
Acute Disease
1
2003
208
0.010
Why?
Immunohistochemistry
1
2003
364
0.010
Why?
Venugopal's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (236)
Explore
_
Co-Authors (20)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_